A ‘Game-Changing’ 15-Minute COVID-19 Test Was Just Cleared in Europe

Becton Dickinson and Co.’s COVID-19 test that returns results in 15 minutes has been cleared for use in countries that accept Europe’s CE marking, the diagnostics maker said Wednesday.

The test is part of a new class of quicker screening tools named for the identifying proteins called antigens they detect on the surface of SARS-CoV-2. Becton Dickinson expects to begin selling the test, which runs on the company’s cellphone-sized BD Veritor Plus System, in European markets at the end of October. It will likely be used by emergency departments, general practitioners and pediatricians.

“It is really a game-changing introduction here in Europe,” said Fernand Goldblat, BD’s head of diagnostics for Europe. Europe was really at the epicenter of the pandemic in April and May, “and unfortunately I think we’re headed back in that direction. So the need will be extremely high,” he said.

Antigen tests have emerged as a valuable tool because they produce results much more quickly than gold-standard PCR diagnostic assays. However, they are generally less accurate. In the U.S., for instance, instructions for BD’s system recommend that negative results be confirmed by a molecular testing method.

Becton Dickinson said its antigen assay is 93.5% sensitive, a measure of how often it correctly identifies infections, and 99.3% specific, the rate of correct negative tests. The data, which differ from the U.S. label’s 84% sensitivity and 100% specificity, come from a new clinical study that was recently submitted to the U.S. Food and Drug Administration, spokesman Troy Kirkpatrick said.

European Inroads

Rapid antigen testing has been making inroads in Europe as well as the U.S. Roche Holding AG said this month it would launch its own 15-minute antigen test to European markets accepting the CE mark. Another test developer, LumiraDx, received CE marking for its antigen test late last month. It said it planned to manufacture 2 million tests in September and as many as 10 million in December.

Becton Dickinson’s Veritor system has been used largely to screen for flu in Europe to date, but the new assay could help drive wider antigen testing adoption, including for influenza and other respiratory viruses, said Goldblat.

The company is currently having conversations in multiple European countries, largely with governments and health authorities, about “where and how our solutions would fit,” he said.

The test is already available in the U.S. Becton Dickinson said it is on track to produce about 8 million each month by October across its global markets, and 12 million monthly by March 2021.

Goldblat declined to comment on how those tests would be allocated in Europe and the U.S., except that “a good portion” would be coming to Europe. Pricing will depend on commitments made and the reimbursement environment in a given country, among other factors, he said.

In the U.S., where regulators cleared the assay in July, the Veritor Plus System has an average selling price of $250 to $300, and the tests themselves are about $20 each.

By Emma Court / Bloomberg

Epidemiologist and cardiologist Dr. Christopher Labos answers your questions on the ins and outs of COVID-19 testing and whether the new rapid test from Ottawa’s Spartan Bioscience could be a game-changer.   »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS Connect with CBC News Online: For breaking news, video, audio and in-depth coverage: http://bit.ly/1Z0m6iX Find CBC News on Facebook: http://bit.ly/1WjG36m Follow CBC News on Twitter: http://bit.ly/1sA5P9H For breaking news on Twitter: http://bit.ly/1WjDyks Follow CBC News on Instagram: http://bit.ly/1Z0iE7O Download the CBC News app for iOS: http://apple.co/25mpsUz Download the CBC News app for Android: http://bit.ly/1XxuozZ

Split Test Monkey Instruction Demo- How To Test Your Website Visitors & Optimize Conversions

VC Splitter Pro

 

1.jpg

Are you missing out on clicks and sales due to poor quality content? Are your users not engaged with your site as much as you hoped? Are you getting traffic but not getting sales? VC Splitter solves this and more through advanced A/B Split Testing that gives you the data on what your actual visitors are interacting with and what needs to be improved.

VC Splitter Pro allows you to Naturally Create A/B Split Tests within Visual Composer, Visualize the performance of each test in terms of views, clicks and bounces, Test combinations of ANY Visual Composer Elements, even from other Addons and Improve your website by analytically determine what tests work and what needs to be improved determining the content your users prefer.

Right now you’re in the dark. You may know the overall analytics of a page, but you can’t diagnose which call to action buttons are getting your users clicking, which headings grab their attention or even what image complements your message the most.We’ve all been there, creating and managing a website is tough – but it doesn’t have to be a guessing game. VC Splitter provides to the minute insight on what users are clicking on, and what content is making them bounce.

Set up as easy as 1-2-3:

  • Simply set up your split tests, naturally within visual composer to get started. Its as easy as three mouse clicks. Then duplicate your original content to create a split test variation and modify it, see what button locations work best, what heading text, what images your users are viewing and clicking and more.

  • It takes the guessing out of website design and development and integrates naturally with the #1 Page Builder for WordPress, Visual Composer.
  • Your website will deliver one “variation” at a time to your visitors, tracking views, clicks, bounces, click through rate and bounce rate and allow you to compare what messaging works best.

Based on what variations of content work best with your targeted audience, adapt and improve your site to retain the increase in clicks, depreciation in bounces and overall better user experience.

Test what content and design works best with your visitors to capture their attention

2.jpg